Vitality Watch

Dossier pubmed review 21-aug-2026
Narrative review or expert overview without new data

Immunometabolic reprogramming via GLP-1 receptor agonists in people with HIV: A multidimensional systemic framework.

Key claim: GLP-1 receptor agonists are promising for cardiometabolic care in people with HIV—reducing visceral adiposity, weight, inflammatory biomarkers, and liver fat—while immunologic and gerotherapeutic applications remain hypothesis-generating.

Abstract

Antiretroviral therapy (ART) has transformed HIV infection into a manageable chronic condition, but pathological weight gain, adipose dysfunction, and persistent inflammation are increasingly prevalent among aging people with HIV (PWH). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 RAs have emerged as transformative therapies, although PWH were underrepresented in pivotal trials. This review integrates randomized trials, observational cohorts, pharmacogenomic studies, and emerging mechanistic evidence within a framework of GLP-1-mediated immunometabolic reprogramming. HIV-specific trials demonstrate reductions in visceral adiposity, body weight, inflammatory biomarkers, and liver fat. Exploratory or preliminary studies suggest possible effects on gut epithelial integrity, immune-cell trafficking, lymphoid pyroptosis, and DNA-methylation aging measures; however, several of these findings remain conference-level, preprint, or post hoc evidence and require prospective validation. We also examine lean-mass loss, weight regain after discontinuation, pharmacogenomic variation, drug access, and research priorities. Overall, GLP-1 RAs are promising components of cardiometabolic care for PWH, but immunologic, gerotherapeutic, and HIV-reservoir applications should currently be considered hypothesis-generating.

Why this matters

People with HIV represent an accelerated-aging population where chronic inflammation, lipodystrophy, and cardiometabolic disease converge, making them an informative test case for whether GLP-1 RAs act beyond glycemic and weight control. The review consolidates cardiometabolic benefit signals while explicitly holding immunologic and gerotherapeutic claims at the hypothesis-generating tier — a useful boundary given the broader hype cycle around GLP-1s as longevity drugs.

Source

Link

Briefing card

Immunometabolic reprogramming via GLP-1 receptor agonists in people with HIV: A multidimensional systemic framework.
Stage: review · pubmed · 21-aug-2026

GLP-1 receptor agonists are promising for cardiometabolic care in people with HIV—reducing visceral adiposity, weight, inflammatory biomarkers, and liver fat—while immunologic and gerotherapeutic applications remain hypothesis-generating.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.5582/bst.2026.01148

build build 880 · 2bcef25 · 2026-11-18